Marker Therapeutics, Inc. (MRKR)
Develops immune cell therapies to fight blood cancers and solid tumors.
$1.18-0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-12.6%
The outlook
Marker Therapeutics is trading near its 52-week lows, well below both its 50- and 200-day moving averages. The three analysts covering the stock unanimously rate it a Strong Buy with an average price target implying substantial upside from current levels. The overall sentiment leans neutral despite the bullish analyst view, reflecting the stock's depressed technical position.
What’s behind the score
Analyst consensusStrong Buy — 1.0 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +567% vs current price
Analyst price target
~12-month · 3 analysts$7.87average target+566.7% vs now
Now $1.18
Low $5.60High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$19.7M
52-wk high
$2.46
52-wk low
$0.81
50-day avg
$1.41
200-day avg
$1.40
Trailing P/E
—